{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:15:28Z","timestamp":1789852528917,"version":"4.0.1"},"reference-count":136,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007698","name":"University of Florida","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007698","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ecl.2019.08.006","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T18:12:44Z","timestamp":1571854364000},"page":"727-750","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Pheochromocytomas and Paragangliomas"],"prefix":"10.1016","volume":"48","author":[{"given":"Sergei G.","family":"Tevosian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans K.","family":"Ghayee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ecl.2019.08.006_bib1","article-title":"Pheochromocytoma and paraganglioma-an update on diagnosis, evaluation, and management","author":"Jain","year":"2019","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"10.1016\/j.ecl.2019.08.006_bib2","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9486","key":"10.1016\/j.ecl.2019.08.006_bib3","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(05)67139-5","article-title":"Phaeochromocytoma","volume":"366","author":"Lenders","year":"2005","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ecl.2019.08.006_bib4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.maturitas.2013.12.009","article-title":"Pheochromocytoma: a review","volume":"77","author":"Tsirlin","year":"2014","journal-title":"Maturitas"},{"key":"10.1016\/j.ecl.2019.08.006_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40200-016-0226-x","article-title":"Does this patient have Pheochromocytoma? a systematic review of clinical signs and symptoms","volume":"15","author":"Soltani","year":"2015","journal-title":"J\u00a0Diabetes Metab Disord"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.006_bib6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ecl.2011.02.002","article-title":"Hypertension in pheochromocytoma: characteristics and treatment","volume":"40","author":"Zuber","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"10.1016\/j.ecl.2019.08.006_bib7","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/00004872-199405000-00015","article-title":"The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients","volume":"12","author":"Anderson","year":"1994","journal-title":"J\u00a0Hypertens"},{"issue":"3","key":"10.1016\/j.ecl.2019.08.006_bib8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1291\/hypres.27.193","article-title":"Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan","volume":"27","author":"Omura","year":"2004","journal-title":"Hypertens Res"},{"issue":"7","key":"10.1016\/j.ecl.2019.08.006_bib9","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/archinte.1987.00370070103015","article-title":"Secondary hypertension in a blood pressure clinic","volume":"147","author":"Sinclair","year":"1987","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.ecl.2019.08.006_bib10","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1210\/er.2002-0013","article-title":"Pheochromocytoma: state-of-the-art and future prospects","volume":"24","author":"Bravo","year":"2003","journal-title":"Endocr Rev"},{"issue":"12","key":"10.1016\/j.ecl.2019.08.006_bib11","first-page":"1471","article-title":"Diagnosis of secondary hypertension: an age-based approach","volume":"82","author":"Viera","year":"2010","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.ecl.2019.08.006_bib12","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-19-0024","article-title":"Genotype-phenotype correlations in pheochromocytoma and paraganglioma","author":"Crona","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"20","key":"10.1016\/j.ecl.2019.08.006_bib13","doi-asserted-by":"crossref","first-page":"6378","DOI":"10.1158\/1078-0432.CCR-09-1237","article-title":"Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients","volume":"15","author":"Erlic","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.ecl.2019.08.006_bib14","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1056\/NEJMoa020152","article-title":"Germ-line mutations in nonsyndromic pheochromocytoma","volume":"346","author":"Neumann","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.ecl.2019.08.006_bib15","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa071407","article-title":"Evidence of MEN-2 in the original description of classic pheochromocytoma","volume":"357","author":"Neumann","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ecl.2019.08.006_bib16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s12022-008-9049-8","article-title":"First description of parathyroid disease in multiple endocrine neoplasia 2A syndrome","volume":"19","author":"Sisson","year":"2008","journal-title":"Endocr Pathol"},{"issue":"7","key":"10.1016\/j.ecl.2019.08.006_bib17","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1210\/jc.2018-02102","article-title":"Fifty years after the first description, the MEN 2B syndrome diagnosis is still late: description of two recent cases","volume":"104","author":"Elisei","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2019.08.006_bib18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1590\/abd1806-4841.20132125","article-title":"Neurofibromatosis: chronological history and current issues","volume":"88","author":"Antonio","year":"2013","journal-title":"An Bras Dermatol"},{"issue":"1","key":"10.1016\/j.ecl.2019.08.006_bib19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.semcancer.2012.05.005","article-title":"Von Hippel-Lindau: how a rare disease illuminates cancer biology","volume":"23","author":"Richard","year":"2013","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.ecl.2019.08.006_bib20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1471-2350-6-39","article-title":"The SDH mutation database: an online resource for succinate dehydrogenase sequence variants involved in pheochromocytoma, paraganglioma and mitochondrial complex II deficiency","volume":"6","author":"Bayley","year":"2005","journal-title":"BMC Med Genet"},{"issue":"5454","key":"10.1016\/j.ecl.2019.08.006_bib21","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1126\/science.287.5454.848","article-title":"Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma","volume":"287","author":"Baysal","year":"2000","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ecl.2019.08.006_bib22","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1677\/ERC-08-0214","article-title":"Mediastinal paragangliomas: association with mutations in the succinate dehydrogenase genes and aggressive behavior","volume":"16","author":"Ghayee","year":"2009","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"10.1016\/j.ecl.2019.08.006_bib23","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.292.8.943","article-title":"Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations","volume":"292","author":"Neumann","year":"2004","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ecl.2019.08.006_bib24","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1210\/jc.2002-020312","article-title":"Familial malignant catecholamine-secreting paraganglioma with prolonged survival associated with mutation in the succinate dehydrogenase B gene","volume":"87","author":"Young","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9263","key":"10.1016\/j.ecl.2019.08.006_bib25","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0140-6736(00)04378-6","article-title":"Germline SDHD mutation in familial phaeochromocytoma","volume":"357","author":"Astuti","year":"2001","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ecl.2019.08.006_bib26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc1013","article-title":"A\u00a0role for mitochondrial enzymes in inherited neoplasia and beyond","volume":"3","author":"Eng","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.ecl.2019.08.006_bib27","first-page":"e187","article-title":"SDHD mutation and pheochromocytoma","volume":"4","author":"Kadiyala","year":"2018","journal-title":"AACE Clin Case Rep"},{"issue":"4","key":"10.1016\/j.ecl.2019.08.006_bib28","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1210\/jc.2018-02411","article-title":"Positive impact of genetic test on the management and outcome of patients with paraganglioma and\/or pheochromocytoma","volume":"104","author":"Buffet","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.006_bib29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer cell"},{"issue":"3702","key":"10.1016\/j.ecl.2019.08.006_bib30","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1126\/science.150.3702.1464","article-title":"Adrenaline synthesis: control by the pituitary gland and adrenal glucocorticoids","volume":"150","author":"Wurtman","year":"1965","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.006_bib31","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00441-018-2795-0","article-title":"Chromaffin cell biology: inferences from The Cancer Genome Atlas","volume":"372","author":"Fishbein","year":"2018","journal-title":"Cell Tissue Res"},{"issue":"9\u201310","key":"10.1016\/j.ecl.2019.08.006_bib32","first-page":"837","article-title":"Counseling patients with succinate dehydrogenase subunit defects: genetics, preventive guidelines, and dealing with uncertainty","volume":"27","author":"Raygada","year":"2014","journal-title":"J\u00a0Pediatr Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2019.08.006_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11906-018-0804-z","article-title":"Pheochromocytomas and hypertension","volume":"20","author":"Pappachan","year":"2018","journal-title":"Curr Hypertens Rep"},{"issue":"7","key":"10.1016\/j.ecl.2019.08.006_bib34","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11906-014-0442-z","article-title":"Diagnosis and management of pheochromocytoma: a practical guide to clinicians","volume":"16","author":"Pappachan","year":"2014","journal-title":"Curr Hypertens Rep"},{"issue":"20","key":"10.1016\/j.ecl.2019.08.006_bib35","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1056\/NEJMimc0806409","article-title":"Interactive medical case. A crisis in late pregnancy","volume":"361","author":"Ross","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ecl.2019.08.006_bib36","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1373\/clinchem.2014.224832","article-title":"Laboratory evaluation of pheochromocytoma and paraganglioma","volume":"60","author":"Eisenhofer","year":"2014","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.006_bib37","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1530\/EJE-17-0077","article-title":"Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma","volume":"177","author":"Rao","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ecl.2019.08.006_bib38","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ijcard.2017.07.014","article-title":"Pheochromocytoma as a reversible cause of cardiomyopathy: analysis and review of the literature","volume":"249","author":"Zhang","year":"2017","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.006_bib39","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/heartjnl-2017-311579","article-title":"Acute stress-induced (takotsubo) cardiomyopathy","volume":"104","author":"Dawson","year":"2018","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.ecl.2019.08.006_bib40","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/BF03346390","article-title":"The many faces of pheochromocytoma","volume":"31","author":"Ghayee","year":"2008","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"4","key":"10.1016\/j.ecl.2019.08.006_bib41","first-page":"496","article-title":"Pheochromocytoma and pregnancy: a case report and review","volume":"37","author":"Santos","year":"2015","journal-title":"J\u00a0Bras Nefrol"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.006_bib42","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/10253890701395896","article-title":"Pheochromocytoma as a catecholamine producing tumor: implications for clinical practice","volume":"10","author":"Zelinka","year":"2007","journal-title":"Stress"},{"issue":"8","key":"10.1016\/j.ecl.2019.08.006_bib43","doi-asserted-by":"crossref","first-page":"757","DOI":"10.4065\/70.8.757","article-title":"Spells: in search of a cause","volume":"70","author":"Young","year":"1995","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.ecl.2019.08.006_bib44","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/clinchem\/38.4.486","article-title":"Biochemical diagnosis of pheochromocytoma by simultaneous measurement of urinary excretion of epinephrine and norepinephrine","volume":"38","author":"Smythe","year":"1992","journal-title":"Clin Chem"},{"issue":"6560","key":"10.1016\/j.ecl.2019.08.006_bib45","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/bmj.293.6560.1474-a","article-title":"Phaeochromocytoma in the elderly: a poorly recognised entity?","volume":"293","author":"Cooper","year":"1986","journal-title":"Br Med J"},{"key":"10.1016\/j.ecl.2019.08.006_bib46","series-title":"Williams textbook of endocrinology","author":"Melmed","year":"2011"},{"issue":"5","key":"10.1016\/j.ecl.2019.08.006_bib47","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1053\/ajem.2000.7341","article-title":"Cardiovascular manifestations of pheochromocytoma","volume":"18","author":"Liao","year":"2000","journal-title":"Am J Emerg Med"},{"issue":"4","key":"10.1016\/j.ecl.2019.08.006_bib48","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4158\/EP11327.OR","article-title":"Cardiac complications as initial manifestation of pheochromocytoma: frequency, outcome, and predictors","volume":"18","author":"Yu","year":"2012","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.ecl.2019.08.006_bib49","first-page":"757","article-title":"Production and secretion of parathyroid hormone-related protein in pheochromocytoma: participation of an alpha-adrenergic mechanism","volume":"76","author":"Mune","year":"1993","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2019.08.006_bib50","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2265.1992.tb02359.x","article-title":"Cushing's syndrome associated with ectopic production of corticotrophin-releasing hormone, corticotrophin and vasopressin by a phaeochromocytoma","volume":"37","author":"O'Brien","year":"1992","journal-title":"Clin Endocrinol"},{"issue":"9","key":"10.1016\/j.ecl.2019.08.006_bib51","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/jjco\/hyi139","article-title":"Hypokalemic rhabdomyolysis due to WDHA syndrome caused by VIP-producing composite pheochromocytoma: a case in neurofibromatosis type 1","volume":"35","author":"Onozawa","year":"2005","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ecl.2019.08.006_bib52","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1210\/jc.2015-2855","article-title":"Cushing syndrome due to ACTH-secreting pheochromocytoma, aggravated by glucocorticoid-driven positive-feedback loop","volume":"101","author":"Sakuma","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2019.08.006_bib53","doi-asserted-by":"crossref","DOI":"10.1530\/EC-18-0318","article-title":"Missed clinical clues in patients with pheochromocytoma\/paraganglioma discovered by imaging","author":"Rogowski-Lehmann","year":"2018","journal-title":"Endocrine Connect"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2019.08.006_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.15.S1.1","article-title":"The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas","volume":"15","author":"Zeiger","year":"2009","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.ecl.2019.08.006_bib55","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1210\/jc.2018-01707","article-title":"Pheochromocytoma characteristics and behavior differ depending on method of discovery","volume":"104","author":"Gruber","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2019.08.006_bib56","doi-asserted-by":"crossref","first-page":"68","DOI":"10.7861\/clinmedicine.19-1-68","article-title":"Endocrinology: phaeochromocytoma","volume":"19","author":"Firth","year":"2019","journal-title":"Clin Med"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.006_bib57","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1152\/physrev.00042.2006","article-title":"Catecholaminergic systems in stress: structural and molecular genetic approaches","volume":"89","author":"Kvetnansky","year":"2009","journal-title":"Physiol Rev"},{"issue":"3","key":"10.1016\/j.ecl.2019.08.006_bib58","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1530\/EJE-13-0882","article-title":"Diagnosis of endocrine disease: biochemical diagnosis of phaeochromocytoma and paraganglioma","volume":"170","author":"van Berkel","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.ecl.2019.08.006_bib59","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMcp065470","article-title":"Clinical practice. The incidentally discovered adrenal mass","volume":"356","author":"Young","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ecl.2019.08.006_bib60","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0033","article-title":"European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma","volume":"174","author":"Plouin","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2019.08.006_bib61","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1023\/A:1011572617314","article-title":"Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma","volume":"2","author":"Eisenhofer","year":"2001","journal-title":"Rev Endocr Metab Disord"},{"issue":"5","key":"10.1016\/j.ecl.2019.08.006_bib62","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1210\/jcem.86.5.7496","article-title":"Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes","volume":"86","author":"Eisenhofer","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ecl.2019.08.006_bib63","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/jama.287.11.1427","article-title":"Biochemical diagnosis of pheochromocytoma: which test is best?","volume":"287","author":"Lenders","year":"2002","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.006_bib64","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1210\/jc.2002-021251","article-title":"A\u00a0comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines","volume":"88","author":"Sawka","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2019.08.006_bib65","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1472-6823-4-2","article-title":"A\u00a0systematic review of the literature examining the diagnostic efficacy of measurement of fractionated plasma free metanephrines in the biochemical diagnosis of pheochromocytoma","volume":"4","author":"Sawka","year":"2004","journal-title":"BMC Endocr Disord"},{"issue":"6","key":"10.1016\/j.ecl.2019.08.006_bib66","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1210\/jc.2002-030005","article-title":"Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results","volume":"88","author":"Eisenhofer","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.006_bib67","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1586\/17446651.2014.887985","article-title":"Pheochromocytoma: pitfalls in the biochemical evaluation","volume":"9","author":"Dobri","year":"2014","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2019.08.006_bib68","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2214\/ajr.170.3.9490968","article-title":"CT time-attenuation washout curves of adrenal adenomas and nonadenomas","volume":"170","author":"Korobkin","year":"1998","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.006_bib69","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1148\/radiol.2342031876","article-title":"Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT","volume":"234","author":"Szolar","year":"2005","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.006_bib70","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1210\/jc.2018-01532","article-title":"CT characteristics of pheochromocytoma: relevance for the evaluation of adrenal incidentaloma","volume":"104","author":"Canu","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.006_bib71","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00441-018-2791-4","article-title":"Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma","volume":"372","author":"Taieb","year":"2018","journal-title":"Cell Tissue Res"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.006_bib72","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.tem.2005.01.007","article-title":"New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas","volume":"16","author":"Ilias","year":"2005","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2019.08.006_bib73","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10689-004-2155-y","article-title":"Imaging of pheochromocytoma and paraganglioma","volume":"4","author":"Brink","year":"2005","journal-title":"Fam Cancer"},{"issue":"1","key":"10.1016\/j.ecl.2019.08.006_bib74","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/110241598750004913","article-title":"Effectiveness and limits of preoperative imaging studies for the localisation of pheochromocytomas and paragangliomas: a review of 282 cases. French Association of Surgery (AFC), and The French Association of Endocrine Surgeons (AFCE)","volume":"164","author":"Jalil","year":"1998","journal-title":"Eur J Surg"},{"issue":"3","key":"10.1016\/j.ecl.2019.08.006_bib75","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1148\/radiology.155.3.4001380","article-title":"Pheochromocytoma and the normal adrenal medulla: improved visualization with I-123 MIBG scintigraphy","volume":"155","author":"Lynn","year":"1985","journal-title":"Radiology"},{"issue":"7","key":"10.1016\/j.ecl.2019.08.006_bib76","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/00006231-199207000-00006","article-title":"A\u00a0pharmacological guide to medicines\u00a0which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG)","volume":"13","author":"Solanki","year":"1992","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.ecl.2019.08.006_bib77","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2018-02355","article-title":"Impact of 123 I-MIBG scintigraphy on clinical decision making in pheochromocytoma and paraganglioma","author":"Rao","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.ecl.2019.08.006_bib78","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.2967\/jnumed.108.052373","article-title":"Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma","volume":"49","author":"Ilias","year":"2008","journal-title":"J\u00a0Nucl Med"},{"issue":"4","key":"10.1016\/j.ecl.2019.08.006_bib79","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrendo.2010.22","article-title":"Diagnosis: imaging of pheochromocytomas and paragangliomas","volume":"6","author":"Chew","year":"2010","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"10.1016\/j.ecl.2019.08.006_bib80","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/jnci\/djs188","article-title":"Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography","volume":"104","author":"Timmers","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.ecl.2019.08.006_bib81","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1210\/jc.2009-1248","article-title":"Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma","volume":"94","author":"Timmers","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ecl.2019.08.006_bib82","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1007\/s00259-012-2156-2","article-title":"Toward tailored medicine (and beyond): the phaeochromocytoma and paraganglioma model","volume":"39","author":"Cuccurullo","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1016\/j.ecl.2019.08.006_bib83","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1007\/s00259-016-3357-x","article-title":"PET\/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT\/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma","volume":"43","author":"Janssen","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.006_bib84","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2967\/jnumed.115.161018","article-title":"68Ga-DOTATATE PET\/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT\/MRI","volume":"57","author":"Janssen","year":"2016","journal-title":"J\u00a0Nucl Med"},{"issue":"8","key":"10.1016\/j.ecl.2019.08.006_bib85","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1007\/s00259-012-2119-7","article-title":"A\u00a0comparison of the performance of (6)(8)Ga-DOTATATE PET\/CT and (1)(2)(3)I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma","volume":"39","author":"Maurice","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.006_bib86","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13139-015-0331-7","article-title":"Diagnostic performance of (68)Ga-DOTATATE PET\/CT, (18)F-FDG PET\/CT and (131)I-MIBG scintigraphy in mapping metastatic pheochromocytoma and paraganglioma","volume":"49","author":"Tan","year":"2015","journal-title":"Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.ecl.2019.08.006_bib87","first-page":"1208","article-title":"Long-term effect of adrenalectomy on cardiovascular remodeling in patients with pheochromocytoma","volume":"102","author":"Majtan","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.006_bib88","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/cen.13252","article-title":"Is there an optimal preoperative management strategy for phaeochromocytoma\/paraganglioma?","volume":"86","author":"Challis","year":"2017","journal-title":"Clin Endocrinol"},{"issue":"9","key":"10.1016\/j.ecl.2019.08.006_bib89","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/jch.12571","article-title":"Treatment of hypertension in children with catecholamine-secreting tumors: a systematic approach","volume":"17","author":"Romero","year":"2015","journal-title":"J\u00a0Clin Hypertens"},{"issue":"11","key":"10.1016\/j.ecl.2019.08.006_bib90","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1210\/jc.2007-1720","article-title":"Preoperative management of the pheochromocytoma patient","volume":"92","author":"Pacak","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"13","key":"10.1016\/j.ecl.2019.08.006_bib91","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMc1817267","article-title":"Ivabradine in catecholamine-induced tachycardia in a patient with paraganglioma","volume":"380","author":"Malaza","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ecl.2019.08.006_bib92","first-page":"5541","article-title":"Improvement of preoperative management in patients with adrenal pheochromocytoma","volume":"7","author":"Li","year":"2014","journal-title":"Int J Clin Exp Med"},{"issue":"1","key":"10.1016\/j.ecl.2019.08.006_bib93","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1245\/s10434-016-5514-7","article-title":"Selective versus non-selective alpha-blockade prior to laparoscopic adrenalectomy for pheochromocytoma","volume":"24","author":"Randle","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.ecl.2019.08.006_bib94","first-page":"190","article-title":"Pheochromocytoma: a review on preoperative treatment with phenoxybenzamine or doxazosin","volume":"72","author":"van der Zee","year":"2014","journal-title":"Neth J Med"},{"issue":"4","key":"10.1016\/j.ecl.2019.08.006_bib95","doi-asserted-by":"crossref","first-page":"368","DOI":"10.4158\/EP14036.RA","article-title":"The Mount Sinai clinical pathway for the management of pheochromocytoma","volume":"21","author":"Galati","year":"2015","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.ecl.2019.08.006_bib96","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/00000658-199011000-00010","article-title":"Surgical management of pheochromocytoma with the use of metyrosine","volume":"212","author":"Perry","year":"1990","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.ecl.2019.08.006_bib97","first-page":"1480","article-title":"Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center","volume":"86","author":"Plouin","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2019.08.006_bib98","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1177\/000313481808400642","article-title":"Predictive factors of operative hemodynamic instability for pheochromocytoma","volume":"84","author":"Aksakal","year":"2018","journal-title":"Am Surg"},{"issue":"3","key":"10.1016\/j.ecl.2019.08.006_bib99","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.surg.2015.09.016","article-title":"Clinical predictors of prolonged postresection hypotension after laparoscopic adrenalectomy for pheochromocytoma","volume":"159","author":"Namekawa","year":"2016","journal-title":"Surgery"},{"issue":"5","key":"10.1016\/j.ecl.2019.08.006_bib100","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.amjsurg.2019.03.016","article-title":"Pheochromocytoma: 20years of improving surgical care","volume":"217","author":"Worrest","year":"2019","journal-title":"Am J Surg"},{"issue":"11","key":"10.1016\/j.ecl.2019.08.006_bib101","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1007\/s00268-017-4095-3","article-title":"Evaluation of open and minimally invasive adrenalectomy: a systematic review and network meta-analysis","volume":"41","author":"Heger","year":"2017","journal-title":"World J Surg"},{"key":"10.1016\/j.ecl.2019.08.006_bib102","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijsu.2018.11.019","article-title":"Risk factors for postoperative severe morbidity after pheochromocytoma surgery: a single center retrospective analysis of 262 patients","volume":"60","author":"Bai","year":"2018","journal-title":"Int J Surg"},{"issue":"3","key":"10.1016\/j.ecl.2019.08.006_bib103","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s00464-015-4294-7","article-title":"Predictive factors for postoperative morbidity after laparoscopic adrenalectomy for pheochromocytoma: a multicenter retrospective analysis in 225 patients","volume":"30","author":"Brunaud","year":"2016","journal-title":"Surg Endosc"},{"issue":"6","key":"10.1016\/j.ecl.2019.08.006_bib104","first-page":"341","article-title":"Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery","volume":"30","author":"Schuttler","year":"1995","journal-title":"Anasthesiol Intensivmed Notfallmed Schmerzther"},{"issue":"5","key":"10.1016\/j.ecl.2019.08.006_bib105","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12542","article-title":"Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis","volume":"81","author":"Niemeijer","year":"2014","journal-title":"Clin Endocrinol"},{"issue":"11","key":"10.1016\/j.ecl.2019.08.006_bib106","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1210\/jc.2012-2356","article-title":"Treatment with sunitinib for\u00a0patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas","volume":"97","author":"Ayala-Ramirez","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.006_bib107","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1210\/jc.2008-1972","article-title":"Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors","volume":"94","author":"Jimenez","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2019.08.006_bib108","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1210\/jc.2008-1836","article-title":"Rationale and evidence for sunitinib in the treatment of malignant paraganglioma\/pheochromocytoma","volume":"94","author":"Joshua","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2019.08.006_bib109","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ng.533","article-title":"Germline mutations in TMEM127 confer susceptibility to pheochromocytoma","volume":"42","author":"Qin","year":"2010","journal-title":"Nat Genet"},{"issue":"24","key":"10.1016\/j.ecl.2019.08.006_bib110","doi-asserted-by":"crossref","first-page":"6162","DOI":"10.1002\/cncr.27675","article-title":"Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas\/paragangliomas","volume":"118","author":"Oh","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.006_bib111","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1210\/en.2012-1854","article-title":"Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in\u00a0vitro and in\u00a0vivo studies in female athymic nude mice","volume":"154","author":"Giubellino","year":"2013","journal-title":"Endocrinology"},{"issue":"7627","key":"10.1016\/j.ecl.2019.08.006_bib112","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature19796","article-title":"Targeting renal cell carcinoma with a HIF-2 antagonist","volume":"539","author":"Chen","year":"2016","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ecl.2019.08.006_bib113","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.006_bib114","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2265.2008.03256.x","article-title":"123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation","volume":"69","author":"Bhatia","year":"2008","journal-title":"Clin Endocrinol"},{"issue":"4","key":"10.1016\/j.ecl.2019.08.006_bib115","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cen.12341","article-title":"(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis","volume":"80","author":"van Hulsteijn","year":"2014","journal-title":"Clin Endocrinol"},{"issue":"5","key":"10.1016\/j.ecl.2019.08.006_bib116","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.semnuclmed.2011.05.003","article-title":"Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology","volume":"41","author":"Vallabhajosula","year":"2011","journal-title":"Semin Nucl Med"},{"issue":"3","key":"10.1016\/j.ecl.2019.08.006_bib117","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/0969-8043(93)90179-E","article-title":"No-carrier-added synthesis of meta-[131I]iodobenzylguanidine","volume":"44","author":"Vaidyanathan","year":"1993","journal-title":"Appl Radiat Isot"},{"issue":"25","key":"10.1016\/j.ecl.2019.08.006_bib118","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","article-title":"Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Gonias","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.ecl.2019.08.006_bib119","first-page":"299","article-title":"Comparison of high-specific-activity ultratrace 123\/131I-MIBG and carrier-added 123\/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution","volume":"25","author":"Barrett","year":"2010","journal-title":"Cancer Biother Radiopharm"},{"issue":"5","key":"10.1016\/j.ecl.2019.08.006_bib120","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J\u00a0Nucl Med"},{"issue":"2\u201303","key":"10.1016\/j.ecl.2019.08.006_bib121","first-page":"117","article-title":"Metastatic phaeochromocytoma: spinning towards more promising treatment options","volume":"127","author":"Nolting","year":"2019","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"4","key":"10.1016\/j.ecl.2019.08.006_bib122","first-page":"334","article-title":"Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma","volume":"52","author":"Forrer","year":"2008","journal-title":"Q\u00a0J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.ecl.2019.08.006_bib123","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma","volume":"102","author":"Kong","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ecl.2019.08.006_bib124","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/jso.24553","article-title":"Peptide receptor radionuclide treatment and (131)I-MIBG in the management of patients with metastatic\/progressive phaeochromocytomas and paragangliomas","volume":"115","author":"Nastos","year":"2017","journal-title":"J\u00a0Surg Oncol"},{"issue":"10","key":"10.1016\/j.ecl.2019.08.006_bib125","first-page":"1599","article-title":"Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma","volume":"47","author":"van Essen","year":"2006","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.006_bib126","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrc3648","article-title":"Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity","volume":"14","author":"Dahia","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.006_bib127","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrendo.2014.188","article-title":"Paraganglioma and phaeochromocytoma: from genetics to personalized medicine","volume":"11","author":"Favier","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"10.1016\/j.ecl.2019.08.006_bib128","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11912-017-0643-0","article-title":"Treatment for malignant pheochromocytomas and paragangliomas: 5 years of progress","volume":"19","author":"Jimenez","year":"2017","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"10.1016\/j.ecl.2019.08.006_bib129","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1055\/s-0031-1299707","article-title":"Metastatic pheochromocytoma and paraganglioma: focus on therapeutics","volume":"44","author":"Plouin","year":"2012","journal-title":"Horm Metab Res"},{"issue":"17","key":"10.1016\/j.ecl.2019.08.006_bib130","first-page":"5615","article-title":"Mutations in the SDHB gene are associated with extra-adrenal and\/or malignant phaeochromocytomas","volume":"63","author":"Gimenez-Roqueplo","year":"2003","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ecl.2019.08.006_bib131","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1371\/journal.pgen.0010008","article-title":"A\u00a0HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas","volume":"1","author":"Dahia","year":"2005","journal-title":"PLoS Genet"},{"issue":"6","key":"10.1016\/j.ecl.2019.08.006_bib132","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ccr.2013.04.018","article-title":"SDH mutations establish a hypermethylator phenotype in paraganglioma","volume":"23","author":"Letouze","year":"2013","journal-title":"Cancer cell"},{"issue":"6","key":"10.1016\/j.ecl.2019.08.006_bib133","doi-asserted-by":"crossref","first-page":"E954","DOI":"10.1210\/jc.2011-3437","article-title":"Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations","volume":"97","author":"Loriot","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"32","key":"10.1016\/j.ecl.2019.08.006_bib134","doi-asserted-by":"crossref","first-page":"32955","DOI":"10.18632\/oncotarget.5106","article-title":"Deciphering the molecular basis of invasiveness in Sdhb-deficient cells","volume":"6","author":"Loriot","year":"2015","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.ecl.2019.08.006_bib135","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2967\/jnumed.114.137034","article-title":"Correlation between in\u00a0vivo 18F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma","volume":"55","author":"van Berkel","year":"2014","journal-title":"J\u00a0Nucl Med"},{"issue":"16","key":"10.1016\/j.ecl.2019.08.006_bib136","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1200\/JCO.2006.09.6297","article-title":"Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma","volume":"25","author":"Timmers","year":"2007","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985291930060X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985291930060X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:45:27Z","timestamp":1760175927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985291930060X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":136,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S088985291930060X"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2019.08.006","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pheochromocytomas and Paragangliomas","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2019.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}